言情小说网

手机浏览器扫描二维码访问

参 考 文 献（第2页）

27.TimsitJF，FarkasJC，BoyerJM，etal.Centralveincatheter-relatedthrombosisinintensivecarepatients：incidence，risksfactors，andrelationshipwithcatheter-relatedsepsis.Chest，1998，114（1）：207-213

28.BurnsKE，McLarenA.Acriticalreviewofthromboembolicplicationsassociatedwithcentralvenouscatheters.CanJAnaesth，2008，55（8）：532-541

29.NapalkovP，FeliciDM，ChuLK，etal.Incidenceofcatheter-relatedplicationsinpatientswithcentralvenousorhemodialysiscatheters：ahealthcareclaimsdatabaseanalysis.BMCCardiovascDisord，2013，13：86

30.KearonC，AklEA，ComerotaAJ，etal.AntithrombotictherapyforVTEdisease：AntithromboticTherapyandPreventionofThrombosis，9thed：AmericanCollegeofChestPhysiciansEvidence-BasedClinicalPracticeGuidelines.Chest，2012，141（2Suppl）：e419S-494S

31.ZhaoY，LiZ，ZhangL，etal.CitrateVersusHeparinLockforHemodialysisCatheters：ASystematicReviewandMeta-analysisofRandomizedControlledTrials.AmJKidneyDis，2014，63（3）：479-490

32.IvanDM，SmithT，AllonM.Doestheheparinlockconcentrationaffecthemodialysiscatheterpatency？ClinJAmSocNephrol，2010，5（8）：1458-1462

33.MoranJ，SunS，KhababaI，etal.Arandomizedtrialparinggentamicincitrateandheparinlocksforcentralvenouscathetersinmaintenancehemodialysispatients.AmJKidneyDis，2012，59（1）：102-107

34.HemmelgarnBR，MoistLM，LokCE，etal.Preventionofdialysiscathetermalfunctionwithrebinanttissueplasminogenactivator.NEnglJMed，2011，364（4）：303-312

35.JainG，AllonM，SaddekniS，etal.Doesheparincoatingimprovepatencyorreduceinfectionoftunneleddialysiscatheters？ClinJAmSocNephrol，2009，4（11）：1787-1790

36.RawsonKM，Newburn-CookCV.Theuseoflow-dosewarfarinasprophylaxisforcentralvenouscatheterthrombosisinpatientswithcancer：ameta-analysis.OncolNursForum，2007，34（5）：1037-1043

37.HiremathS，HoldenRM，FergussonD，etal.Antiplateletmedicationsinhemodialysispatients：asystematicreviewofbleedingrates.ClinJAmSocNephrol，2009，4（8）：1347-1355

38.MermelLA，AllonM，BouzaE，etal.Clinicalpracticeguidelinesforthediagnosisandmanagementofintravascularcatheter-relatedinfection：2009UpdatebytheInfectiousDiseasesSocietyofAmerica.ClinInfectDis，2009，49（1）：1-45

39.LokCE，MokrzyckiMH.Preventionandmanagementofcatheter-relatedinfectioninhemodialysispatients.KidneyInt，2011，79（6）：587-598

40.YonCK，LowCL.Sodiumcitrate4%versusheparinasalocksolutioninhemodialysispatientswithcentralvenouscatheters.AmJHealthSystPharm，2013，70（2）：131-136

41.JafferY，SelbyNM，TaalMW，etal.Ameta-analysisofhemodialysiscatheterlockingsolutionsinthepreventionofcatheter-relatedinfection.AmJKidneyDis，2008，51（2）：233-241

42.WarkentinTE.Heparin-inducedthrombocytopeniaintheICU：atransatlanticperspective.Chest，2012，142（4）：815-816

43.YamamotoS，KoideM，MatsuoM，etal.Heparin-inducedthrombocytopeniainhemodialysispatients.AmJKidneyDis，1996，28（1）：82-85

44.HutchisonCA，DasguptaI.Nationalsurveyofheparin-inducedthrombocytopeniainthehaemodialysispopulationoftheUKpopulation.NephrolDialTransplant，2007，22（6）：1680-1684

45.DavenportA.Managementofheparin-inducedthrombocytopeniaduringcontinuousrenalreplacementtherapy.AmJKidneyDis，1998，32（4）：E3

46.DavenportA.Antibodiestoheparin-plateletfactor4plex：pathogenesis，epidemiology，andmanagementofheparin-inducedthrombocytopeniainhemodialysis.AmJKidneyDis，2009，54（2）：361-374

47.LinkinsLA，DansAL，MooresLK，etal.Treatmentandpreventionofheparin-inducedthrombocytopenia：AntithromboticTherapyandPreventionofThrombosis，9thed：AmericanCollegeofChestPhysiciansEvidence-BasedClinicalPracticeGuidelines.Chest，2012，141（2Suppl）：e495S-530S

48.CubattoliL，TeruzziM，CormioM，etal.CitrateanticoagulationduringCVVHinhighriskbleedingpatients.IntJArtifOrgans，2007，30（3）：244-252

49.KramerL，BauerE，JoukhadarC，etal.Citratepharmacokineticsandmetabolismincirrhoticandnoncirrhoticcriticallyillpatients.CritCareMed，2003，31（10）：2450-2455

50.HetzelGR，TaskayaG，SuckerC，etal.Citrateplasmalevelsinpatientsunderregionalanticoagulationincontinuousvenovenoushemofiltration.AmJKidneyDis，2006，48（5）：806-811

51.BellomoR，CassA，ColeL，etal.Intensityofcontinuousrenal-replacementtherapyincriticallyillpatients.NEnglJMed，2009，361（17）：1627-1638

52.PalevskyPM，ZhangJH，O’ConnorTZ，etal.Intensityofrenalsupportincriticallyillpatientswithacutekidneyinjury.NEnglJMed，2008，359（1）：7-20

53.YangY，ZhangP，CuiY，etal.Hypophosphatemiaduringcontinuousveno-venoushemofiltrationisassociatedwithmortalityincriticallyillpatientswithacutekidneyinjury.CritCare，2013，17（5）：R205

54.DrumlW.Metabolicaspectsofcontinuousrenalreplacementtherapies.KidneyIntSuppl，1999，（72）：S56-S61